Medtronic (NYSE:MDT) Updates FY 2026 Earnings Guidance

Medtronic (NYSE:MDT) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 5.620-5.660 for the period, compared to the consensus estimate of 5.630. The company issued revenue guidance of -, compared to the consensus revenue estimate of $35.8 billion.

Analyst Ratings Changes

A number of brokerages have recently issued reports on MDT. Stifel Nicolaus upped their price objective on Medtronic from $90.00 to $105.00 and gave the stock a “hold” rating in a research note on Thursday, October 9th. Leerink Partners set a $120.00 price objective on shares of Medtronic and gave the company an “outperform” rating in a research report on Wednesday. Jefferies Financial Group reaffirmed a “hold” rating and issued a $110.00 target price on shares of Medtronic in a report on Wednesday. JPMorgan Chase & Co. raised their target price on shares of Medtronic from $90.00 to $100.00 and gave the company a “neutral” rating in a research note on Thursday, November 13th. Finally, Robert W. Baird lifted their price target on Medtronic from $103.00 to $109.00 and gave the stock a “neutral” rating in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and twelve have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $108.50.

Medtronic Stock Performance

Shares of Medtronic stock opened at $100.12 on Thursday. The company has a current ratio of 2.01, a quick ratio of 1.50 and a debt-to-equity ratio of 0.54. The company has a market cap of $128.42 billion, a PE ratio of 27.58, a price-to-earnings-growth ratio of 2.42 and a beta of 0.77. The company has a 50 day moving average of $94.80 and a 200-day moving average of $90.70. Medtronic has a 1-year low of $79.29 and a 1-year high of $102.59.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The company had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same quarter in the previous year, the firm earned $1.26 EPS. Medtronic’s revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities research analysts forecast that Medtronic will post 5.46 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Medtronic news, Director William R. Jellison purchased 2,500 shares of the business’s stock in a transaction dated Monday, August 25th. The shares were bought at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the completion of the acquisition, the director owned 5,000 shares in the company, valued at approximately $461,850. This trade represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Harry Skip Kiil sold 8,605 shares of Medtronic stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the transaction, the executive vice president directly owned 35,615 shares in the company, valued at $3,261,621.70. The trade was a 19.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.26% of the stock is currently owned by corporate insiders.

Institutional Trading of Medtronic

Several institutional investors have recently added to or reduced their stakes in the stock. Sunbelt Securities Inc. raised its holdings in Medtronic by 14.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 3,696 shares of the medical technology company’s stock worth $352,000 after purchasing an additional 477 shares during the last quarter. Captrust Financial Advisors increased its position in shares of Medtronic by 4.3% during the third quarter. Captrust Financial Advisors now owns 134,518 shares of the medical technology company’s stock worth $12,811,000 after buying an additional 5,515 shares during the period. Advisory Services Network LLC raised its stake in Medtronic by 4.5% during the third quarter. Advisory Services Network LLC now owns 79,432 shares of the medical technology company’s stock worth $7,565,000 after buying an additional 3,400 shares during the last quarter. Financial Engines Advisors L.L.C. raised its stake in Medtronic by 19.6% during the third quarter. Financial Engines Advisors L.L.C. now owns 2,928 shares of the medical technology company’s stock worth $279,000 after buying an additional 479 shares during the last quarter. Finally, Morningstar Investment Management LLC lifted its holdings in Medtronic by 97.7% in the third quarter. Morningstar Investment Management LLC now owns 44,991 shares of the medical technology company’s stock valued at $4,285,000 after buying an additional 22,229 shares during the period. 82.06% of the stock is currently owned by institutional investors.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.